Although use of the cyclooxygenase (COX)-2 inhibitor celecoxib has demonstrated benefit in preventing premalignant colorectal adenomas, generally the agent should not be recommended for this purpose due to the risk of cardiovascular events, according to 1 recent trial. In a second study of celecoxib use and adenomas, treatment with celecoxib 400 mg/d markedly lowered the incidence of colorectal adenomas within 2 years after the removal of polyps.
Although use of the cyclooxygenase (COX)-2 inhibitor celecoxib has demonstrated benefit in preventing premalignant colorectal adenomas, generally the agent should not be recommended for this purpose due to the risk of cardiovascular events, according to 1 recent trial. In a second study of celecoxib use and adenomas, treatment with celecoxib 400 mg/d markedly lowered the incidence of colorectal adenomas within 2 years after the removal of polyps.
The first trial, the Adenoma Prevention with Celecoxib (APC) randomized, placebo-controlled trial, focused on the potential for celecoxib to lower the incidence of colorectal adenomas found via endoscopy. Efficacy of the drug in prevention of colorectal cancer was not measured. From 1999 to 2002, participants were recruited (age range, 31 to 88 years) from 91 clinical sites across the United States, Canada, and the United Kingdom. All patients had adenomas removed prior to the study's start and had a high likelihood of recurrent adenomas based on number or size of previous adenomas.
To test celecoxib's safety and anti-tumor effectiveness, 2,035 patients were randomly assigned to placebo (679 patients) or celecoxib 200 mg BID (685 patients) or 400 mg BID (671 patients). The stratification was determined according to whether patients used low-dose aspirin (≤325 mg every other day or ≤162.5 mg every day). After randomization, colonoscopies were conducted at Years 1 and 3 of follow-up. At 2-month intervals, patients were asked to report use of concomitant medication and adverse effects.
A total of 89.5% (n=1,822) of the randomized patients received follow-up colonoscopies at Year 1; 75.7% (n=1,541) had the procedure at Year 3. Due to a higher occurrence of cardiovascular events in groups taking celecoxib, drug use was discontinued in 2004.
For those taking placebo, 354 patients developed ≥1 adenoma; of those taking celecoxib 200 mg BID, 252 went on to develop ≥1 adenoma; 213 patients taking celecoxib 400 mg BID also developed ≥1 adenoma. By Year 3, estimated cumulative incidence of locating ≥1 adenoma was 60.7% for those receiving placebo; 43.2% for those receiving 200 mg BID (RR=0.67; 95% CI, 0.59– 0.77; P<.001); and 37.5% of patients taking 400 mg BID (RR=0.55; 95% CI, 0.48–0.64; P<.001). Significant adverse events affected 23% of participants in the 400-mg BID group (RR=1.2; 95% CI, 1.0–1.5; P=.06); 20.4% of those in the 200-mg BID group (RR=1.1; 95% CI, 0.9–1.3; P=.5); and 18.8% of the placebo group. An increased risk of cardiovascular occurrences was linked to celecoxib compared with placebo (RR for celecoxib 200 mg BID=2.6; 95% CI, 1.1– 6.1; RR for celecoxib 400 mg BID=3.4; 95% CI, 1.5–7.9).
The authors noted that they did not directly evaluate the effect of celecoxib on colorectal cancer. They stated that further research may have benefit to those at highest risk for colorectal cancer, as celecoxib was proven efficacious in the prevention of more advanced lesions.
The trial was sponsored by Pfizer and the National Cancer Institute.
The second trial, Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP), was a randomized, placebo-controlled, double-blind study of celecoxib 400 mg/d. A total of 1,561 patients across 107 sites in 32 countries who had had adenomas removed before enrollment were randomly assigned to celecoxib (n=933) or placebo (n=628). Participants were stratified based on use/nonuse of aspirin.
Detection of adenomas at Years 1 or 3 via endoscopy was the primary end point.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More